Quarterly report pursuant to Section 13 or 15(d)

Interim Consolidated Statements Of Operations (unaudited)

v3.20.1
Interim Consolidated Statements Of Operations (unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Income Statement [Abstract]    
Research and development ("R&D") expenses, net $ 3,908 $ 2,743
General and administrative expenses 2,058 981
Operating Loss 5,966 3,724
Finance income, net (65) (499)
Net Loss $ 5,901 $ 3,225
Basic and diluted loss per Ordinary Shares $ 0.26 $ 2.2
Weighted average number of Ordinary Shares outstanding, basic and diluted 22,897,723 2,005,043